摘要:
Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic filariasis, onchocerciasis, dracunculiasis, ascariasis, trichuriasis, strongyloidiasis, trichostrongyliasis, trichomoniasis or cestodiasis. Compounds of formula I of the invention are capable of treating and/or preventing the above-identified diseases:
摘要:
A metal complex compound having a partial structure represented by the general formula: (I) [wherein the moiety B is a benzene ring residue having groups R1 to R4 which each independently represent H, etc. provided that at least one of the groups R1 to R4 is CN; R1 may be bonded with R2, R2 with R3 and R3 with R4 to thereby form a ring structure; the moiety A represents a C3-C20 cyclic structure having at least one C=N bond which may have a substituent and may form a ring structure with the above R4 included therein; and M is Ir, Rh, Pt or Pd]. There is further provided an organic electroluminescence device comprising a pair of electrodes and, interposed therebetween, one or multiple organic thin-film layers having at least a light emitting layer, wherein at least one of the organic thin-film layers contains the above metal complex compound. The organic electroluminescence device emits light when voltage is applied between the electrodes with high luminous efficiency, and the service life of the organic electroluminescence device is prolonged.
摘要:
The invention relates to the pyridinyl-isoxazoles of general formula (I) and the salts thereof, wherein Q represents one of the groups Q1, Q2 or Q3; R1, R2 and R3 represent different groups and n is 0 to 2.
摘要:
The invention provides a process for producing microcapsules with UV filter activity, wherein at least one type of crosslinkable chromophore with UV-A and/or UV-B and/or UV-C filter activity and optionally at least one type of crosslinkable monomer which does not have UV-A and/or UV-B and/or UV-C filter activity are subjected to a crosslinking reaction in the absence of non-crosslinkable chromophores with UV-A and/or UV-B and/or UV-C filter activity and microcapsules obtainable by this process.
摘要:
The present invention relates to a novel malononitrile compound represented by the formula (I): wherein, R1 represents a C1 to C5 (halo)alkyl and the like, R2 represents a C1 to C5 (halo)alkyl, R3 and R4 are the same or different and are a C1 to C6 (halo)alkyl and the like, R5 represents a halogen atom and the like, n is an integer of 0 to 4 and when n is 2 or more, R5 may be the same or different. The malononitrile compound has an efficient pesticidal activity and can control effectively pests such as insect pests, acarine pests, nematode pests and the like.
摘要:
N,N-substituted cyclic amine derivatives represented by general formula (VIII) or pharmacologically acceptable salts thereof: wherein A represents aryl, etc.; E represents -CO- or -CHOH-; G represents oxygen, etc.; J represents optionally substituted aryl; R1 represents lower alkyl, etc.; Alk represents linear or branched lower alkylene; n, v, w, x and y independently represent each 0 or 1; and p represents 2 or 3. These compounds or salts thereof are efficacious in treating diseases against which calcium antagonism is efficacious. These diseases include cerebrovascular disorder at the acute stage, cerebral stroke, cerebral infarction, head injury, cerebral nerve cell death, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, brain circulatory disturbance, brain function disturbance, pain, convulsion, schizophrenia, hemicrania, epilepsy, circular psychosis, nerve degeneration diseases, brain ischemia, AIDS, complex dementia, edema, anxiety and diabetic nephropathy.
摘要:
The invention provides a process for the production of a compound of formula (A), or a pharmaceutically acceptable salt or solvate thereof, wherein R1 represents C¿1-4? alkoxy optionally substituted by one or more fluorine atoms; R?2¿ represents H or C¿1-6? alkoxy optionally substituted by one or more fluorine atoms; R?3¿ represents a 5- or 6-membered heterocyclic ring which is optionally substituted; R4 is a 4-, 5-, 6- or 7-membered heterocyclic ring which is optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring, the ring system as a whole being optionally substituted; the process comprising condensing a compound of formula (B), wherein R1 to R3 are as defined above; with a compound of formula (C), wherein R?5 and R6¿ taken together with the N atom to which they are attached represent a 4-, 5-, 6-, or 7-membered N-containing heterocyclic ring, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring, the ring system as a whole being optionally substituted.
摘要翻译:本发明提供了制备式(A)化合物或其药学上可接受的盐或溶剂合物的方法,其中R 1代表C 1-4 - 任选被一个或多个氟原子取代的烷氧基; R 2代表H或C 1 -6? 任选被一个或多个氟原子取代的烷氧基; R 3'代表任选被取代的5或6元杂环; R4是任选地与苯环或5或6元杂环稠合的4-,5-,6-或7-元杂环,所述环体系作为整体任选被取代; 该方法包括缩合式(B)的化合物,其中R 1至R 3如上所定义; 与式(C)的化合物反应,其中R 5和R 6与它们所连接的N原子一起代表4-,5-,6-或7-元含N杂环,该环 任选与苯环或5-或6-元杂环稠合,所述环体系作为整体任选被取代。
摘要:
The invention provides a process for the production of a compound of formula (A) or a pharmaceutically acceptable salt or solvate thereof, formula (A), which comprises condensing a compound of formula (B),with a compound of formula (C). Compounds of formula (A) are useful in the treatment of benign prostatic hyperplasia.